TR Harring, NT Nguyen, JA Goss and CA OâMahony
Introduction: The human T cell lymphoma virus was screened for previously in organ donors secondary to concern for progressive disease in an immunocompromised host. However, due to the low prevalence of the virus, a shortage of suitable allografts, and the lack of a time effective test, this practice has been abandoned in the United States. The human T cell lymphoma virus type I may cause progression to several diseases, including human T cell lymphoma virus associated myelopathy, and adult T cell lymphoma/l eukemia. Moreover, there is an overall lack of data relating to the safety profile in the medical literature with use of human T cell lymphoma virus positive allografts.
Aim: To determine the safety of human T cell lymphoma virus positive allografts in orthotopic liver transplantation.
Materials and Methods: Our database was queried for recipients of known human T cell lymphoma virus positive allografts at time of transplantation. We present one patient case report followed by a review of the medical literature.
Results: The patient was transplanted secondary to cirrhosis due to alcohol and hepatitis C virus infection with hepatocellular carcinoma. When a suitable allograft became available, the patient was advised that it was human T cell lymphoma virus type I positive. The risks and benefits were discussed thoroughly with the patient and he elected to proceed with the operation. His operation and post operative course were unremarkable. He continues to do well during on follow up of over 777 day s, and currently he has no symptoms of any human T cell lymphoma virus associated disease. Review of the medical literature demonstrates few reports on human T cell lymphoma virus related complications after orthotopic liver transplantation; however, the re are theories that immunosuppresion may cause progressive disease in these patients.
Conclusions: Human T cell lymphoma virus type I positive donors can be life saving sources of allografts. Our center supports the use of these allografts in patients that otherwise continue to be on the waiting list.
Nursaheker
DOI: 10.37421/2161-0991.2023.13.242
DOI: 10.37421/2161-0991.2023.13.241
DOI: 10.37421/2161-0991.2023.13.243
Congenital glaucoma is a rare but severe ocular condition that can lead to vision impairment or blindness if left untreated. Penetrating Keratoplasty (PKP) has emerged as a viable surgical option to restore vision in individuals with congenital glaucoma who present with corneal opacity. This paper presents a comprehensive review of the surgical procedure, outcomes and challenges associated with PKP in congenital glaucoma. Through an extensive literature review, we examine the key factors influencing surgical success, such as patient selection, donor corneal grafts and postoperative management. We discuss the potential complications and long-term outcomes while emphasizing the importance of early intervention and long-term follow-up in achieving optimal results. In conclusion, PKP offers a promising approach for vision restoration in congenital glaucoma patients and serves as a crucial component of a multi-disciplinary approach in managing this challenging condition.
DOI: 10.37421/2161-0991.2023.13.244
Solid organ transplant recipients are at an increased risk of developing skin cancer due to long-term immunosuppressive medication use. This review explores the complex relationship between immunity, immunosuppressive drugs and the occurrence of Non-Melanoma Skin Cancers (NMSCs) in transplant recipients. We analyze key factors affecting skin cancer risk, including type and dosage of immunosuppressive medications, as well as individual patient characteristics. The literature review suggests that achieving a delicate balance between preventing graft rejection and reducing skin cancer risk is a challenge. We discuss strategies for mitigating NMSC risk, such as the use of alternative immunosuppressive regimens and vigilant dermatological monitoring. Ultimately, a multidisciplinary approach is required to ensure the overall well-being of transplant recipients.
DOI: 10.37421/2161-0991.2023.13.245
Lung transplant recipients represent a vulnerable population at the intersection of autoimmunity and the COVID-19 pandemic. This review explores the complex interplay between post-transplant autoimmunity and COVID-19 in lung transplant recipients. We analyse the unique challenges faced by these patients, including increased susceptibility to infections, potential exacerbation of autoimmune reactions and the impact of immunosuppressive therapies. Key considerations include risk assessment, vaccination strategies and the evolving landscape of management protocols. By navigating this crossroads with a multidisciplinary approach that integrates immunology, transplantation and infectious disease expertise, healthcare providers can optimize patient care and outcomes.
DOI: 10.37421/2161-0991.2023.13.246
Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency disorder characterized by dysfunctional phagocytes, rendering affected individuals highly susceptible to recurrent and severe infections. Hematopoietic Stem Cell Transplantation (HSCT) has emerged as a promising curative therapy for CGD, offering the potential for restored immune function. This review explores the clinical application of HSCT in CGD, analyzing the historical and contemporary aspects of the procedure, associated challenges and patient outcomes. Keywords include risk assessment, donor selection, Graft-Versus-Host Disease (GVHD), conditioning regimens and long-term follow-up. The findings underscore the significance of HSCT as a potentially curative approach for CGD, while emphasizing the importance of continued research and multidisciplinary collaboration for optimal patient care.
DOI: 10.37421/2161-0991.2023.13.239
DOI: 10.37421/2161-0991.2023.13.238
DOI: 10.37421/2161-0991.2023.13.240
Transplantation Technologies & Research received 223 citations as per Google Scholar report